Bill Anderson
Chairman of the Board of Management and Chief Executive OfficerBayer
PharmaceuticalsView Profile →Chief Executive Officer · Novartis
Vasant Narasimhan is chief executive officer of Novartis. A physician with public-policy training, he advanced through vaccines, development and chief medical officer roles before becoming CEO in 2018.
Last reviewed: Nov 15, 2026
Vasant Narasimhan is chief executive officer of Novartis. A physician with public-policy training, he advanced through vaccines, development and chief medical officer roles before becoming CEO in 2018.
Narasimhan studied biological sciences at the University of Chicago before completing medicine at Harvard Medical School and a public-policy master’s degree at Harvard Kennedy School. During and after medical training, he worked on HIV/AIDS, malaria and tuberculosis issues in India, Africa and South America.
He joined Novartis in 2005. From 2008 to 2012 he led the North American vaccines region and served as US country president for Vaccines and Diagnostics. He then became global head of Development for Novartis Vaccines.
In 2014 Narasimhan briefly headed Biopharmaceuticals and Oncology Injectables at Sandoz before taking global development responsibility for Novartis Pharmaceuticals. He became global head of Drug Development and chief medical officer in 2016.
Narasimhan moved into the CEO role in 2018. His subsequent leadership has focused Novartis on innovative medicines and selected therapeutic areas and technology platforms, including radioligand, RNA and cell-and-gene therapies. Outside the company, he has supported public-health and conservation organizations, including African Parks.
Doctor of Medicine — Harvard Medical School.
Master’s degree — Harvard Kennedy School — Public Policy.
Bachelor’s degree — University of Chicago — Biological Sciences.